Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02502162 · ClinicalTrials.gov registry record · NA
Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
A NA study of Complex Regional Pain Syndrome, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT02502162: Recruiting NA study of Complex Regional Pain Syndrome, sponsored by Stanford University.
NCT02502162 is a NA study of Complex Regional Pain Syndrome that is actively recruiting participants, run by Stanford University. The registered enrollment target is 120 participants, below the 231-participant average among 3 other Complex Regional Pain Syndrome trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02502162, a NA study of Complex Regional Pain Syndrome, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.
Primary Outcome
Daily pain reports on a 0-10 numerical rating scale for pain, where 0=no pain and 10=pain as bad as you can imagine
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LDN
Study Locations (1)
California
- Stanford University - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2015-06 |
| Est. Completion | 2027-07 |
| Phase | NA |
What NCT02502162 shows while recruiting
NCT02502162 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 231-participant average among 3 other Complex Regional Pain Syndrome trials with a reported enrollment target (48% lower).
The record links to 1 condition, with Complex Regional Pain Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02502162 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02502162 about?
NCT02502162 is a clinical study titled "Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome". The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend eit...
What is the current status of trial NCT02502162?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2015-06. Estimated completion is 2027-07.
What conditions does trial NCT02502162 study?
This clinical trial studies the following conditions: Complex Regional Pain Syndrome.
What interventions are being tested in trial NCT02502162?
The interventions under investigation include: Placebo (DRUG), LDN (DRUG).
Who is sponsoring clinical trial NCT02502162?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02502162 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Complex Regional Pain Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects and Mechanisms of a High CBD Cannabis Extract (BRC-002) for the Treatment of Pain and Health in Complex Regional Pain Syndrome
RECRUITING · Phase 1
-
Safety of Intravenous Neridronic Acid in CRPS
COMPLETED · Phase 3
-
A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia